文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变:数据与疗效综述

Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy.

作者信息

Iacono Pierluigi, Da Pozzo Stefano, Varano Monica, Parravano Mariacristina

机构信息

IRCCS-Fondazione Bietti, Via Livenza 3, 00198 Rome, Italy.

TSRetina, 34121 Trieste, Italy.

出版信息

Pharmaceuticals (Basel). 2020 Oct 29;13(11):349. doi: 10.3390/ph13110349.


DOI:10.3390/ph13110349
PMID:33137968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7692681/
Abstract

Central serous chorioretinopathy represents the fourth most frequent retinal disorder, occurring especially in young age. Central serous chorioretinopathy is mainly characterized by macular serous retinal detachment and although the clinical course moves frequently toward a spontaneous resolution, the subretinal fluid may persist for a long time, thus evolving to the chronic form, and leading to a potential damage of the retinal pigment epithelium and to photoreceptors. The photodynamic therapy with verteporfin plays an important role in the armamentarium among the many therapeutic options employed in this complex retinal disorder. In this review, the authors aim to summarize data of efficacy and safety of PDT focusing especially on mechanisms of action of the PDT and providing comparative outcomes with the alternative therapeutic approaches, including especially the subthreshold laser treatment.

摘要

中心性浆液性脉络膜视网膜病变是第四常见的视网膜疾病,尤其好发于年轻人。中心性浆液性脉络膜视网膜病变主要特征为黄斑区浆液性视网膜脱离,尽管临床病程常趋向于自发缓解,但视网膜下液可能长期持续存在,进而演变为慢性形式,并导致视网膜色素上皮和光感受器的潜在损害。在这种复杂视网膜疾病所采用的众多治疗选择中,维替泊芬光动力疗法在治疗手段中发挥着重要作用。在本综述中,作者旨在总结光动力疗法的疗效和安全性数据,特别关注光动力疗法的作用机制,并提供与其他治疗方法(尤其是阈下激光治疗)的对比结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/7692681/22b0bf27a709/pharmaceuticals-13-00349-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/7692681/9edca1578c49/pharmaceuticals-13-00349-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/7692681/22b0bf27a709/pharmaceuticals-13-00349-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/7692681/9edca1578c49/pharmaceuticals-13-00349-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1629/7692681/22b0bf27a709/pharmaceuticals-13-00349-g002.jpg

相似文献

[1]
Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy.

Pharmaceuticals (Basel). 2020-10-29

[2]
Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments.

Curr Pharm Des. 2018

[3]
Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.

Retina. 2011-10

[4]
Bullous Central Serous Chorioretinopathy: A Rare and Atypical Form of Central Serous Chorioretinopathy. A Systematic Review.

Pharmaceuticals (Basel). 2020-8-28

[5]
Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy.

Am J Ophthalmol. 2003-10

[6]
A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.

JAMA Ophthalmol. 2015-3

[7]
Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy.

Ophthalmic Surg Lasers Imaging. 2009

[8]
COMPARISON OF HALVING THE IRRADIATION TIME OR THE VERTEPORFIN DOSE IN PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Retina. 2015-12

[9]
Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report.

J Med Case Rep. 2011-5-26

[10]
Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

Korean J Ophthalmol. 2019-12

引用本文的文献

[1]
Photodynamic treatment without verteporfin in chronic central serous chorioretinopathy.

BMC Ophthalmol. 2025-5-23

[2]
Predictive Factors for Morphological and Functional Improvements in Long-Lasting Central Serous Chorioretinopathy Treated with Photodynamic Therapy.

Biomedicines. 2025-4-11

[3]
Verteporfin Photodynamic Therapy for the Treatment of Chorioretinal Conditions: A Narrative Review.

Clin Ophthalmol. 2024-6-10

[4]
Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy.

Adv Ophthalmol Pract Res. 2024-1-23

[5]
Three-Year Follow-Up Detecting Choroidal Neovascularization with Swept Source Optical Coherence Tomography Angiography (SS-OCTA) after Successful Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

Diagnostics (Basel). 2023-8-29

[6]
Half-Fluence, Half-Dose Photodynamic Therapy: Less Direct Damage but More Inflammation?

Pharmaceuticals (Basel). 2023-3-27

[7]
The Contemporary Role of Photodynamic Therapy in the Treatment of Pachychoroid Diseases.

J Ophthalmol. 2021-10-23

[8]
Multifocal electroretinography-assisted anatomical and functional evaluation of subthreshold green laser in acute central serous chorioretinopathy.

Indian J Ophthalmol. 2021-9

本文引用的文献

[1]
Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy.

Int J Ophthalmol. 2020-9-18

[2]
Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy.

Biomed Res Int. 2020

[3]
Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy.

Br J Ophthalmol. 2021-6

[4]
Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy.

Br J Ophthalmol. 2021-4

[5]
Fluorescein angiography as a primary guide for reduced-fluence photodynamic therapy for the treatment of chronic central serous chorioretinopathy.

Int Ophthalmol. 2020-7

[6]
Comment on: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.

Am J Ophthalmol. 2020-4

[7]
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.

Lancet. 2020-1-25

[8]
Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

Korean J Ophthalmol. 2019-12

[9]
Three-Year Results of Fluorescein Angiography-Guided Standard Photodynamic Therapy with Multiple Spots for Central Serous Chorioretinopathy.

Ophthalmol Retina. 2018-7

[10]
Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.

Am J Ophthalmol. 2019-4-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索